These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26076586)

  • 1. Clinical indicators for recurrent cardiovascular events in acute coronary syndrome patients treated with statins under routine practice in Thailand: an observational study.
    Chinwong D; Patumanond J; Chinwong S; Siriwattana K; Gunaparn S; Hall JJ; Phrommintikul A
    BMC Cardiovasc Disord; 2015 Jun; 15():55. PubMed ID: 26076586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins for acute coronary syndrome.
    Vale N; Nordmann AJ; Schwartz GG; de Lemos J; Colivicchi F; den Hartog F; Ostadal P; Macin SM; Liem AH; Mills EJ; Bhatnagar N; Bucher HC; Briel M
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD006870. PubMed ID: 25178118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins for acute coronary syndrome.
    Vale N; Nordmann AJ; Schwartz GG; de Lemos J; Colivicchi F; den Hartog F; Ostadal P; Macin SM; Liem AH; Mills E; Bhatnagar N; Bucher HC; Briel M
    Cochrane Database Syst Rev; 2011 Jun; (6):CD006870. PubMed ID: 21678362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in total recurrent cardiovascular events in acute coronary syndrome patients with low-density lipoprotein cholesterol goal <70 mg/dL: a real-life cohort in a developing country.
    Chinwong S; Patumanond J; Chinwong D; Hall JJ; Phrommintikul A
    Ther Clin Risk Manag; 2016; 12():353-60. PubMed ID: 27042081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term secondary prevention and outcome following acute coronary syndrome: real-world results from the Swedish Primary Care Cardiovascular Database.
    Bentzel S; Ljungman C; Hjerpe P; Schiöler L; Manhem K; Bengtsson Boström K; Kahan T; Mourtzinis G
    Eur J Prev Cardiol; 2024 May; 31(7):812-821. PubMed ID: 38135289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High remnant lipoprotein predicts recurrent cardiovascular events on statin treatment after acute coronary syndrome.
    Nguyen SV; Nakamura T; Kugiyama K
    Circ J; 2014; 78(10):2492-500. PubMed ID: 25168189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Early treatment of statins after acute coronary syndrome?].
    Hamm CW
    Dtsch Med Wochenschr; 2011 Sep; 136(39):1941. PubMed ID: 21948603
    [No Abstract]   [Full Text] [Related]  

  • 8. Association of anhedonia with recurrent major adverse cardiac events and mortality 1 year after acute coronary syndrome.
    Davidson KW; Burg MM; Kronish IM; Shimbo D; Dettenborn L; Mehran R; Vorchheimer D; Clemow L; Schwartz JE; Lespérance F; Rieckmann N
    Arch Gen Psychiatry; 2010 May; 67(5):480-8. PubMed ID: 20439829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of intensive lipid-lowering therapies in patients with acute coronary syndrome: a systematic review and meta-analysis.
    Wu XD; Ye XY; Liu XY; Lin Y; Lin X; Li YY; Ye BH; Sun JC
    Ann Med; 2024 Dec; 56(1):2389470. PubMed ID: 39126262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
    Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
    Schwartz GG; Bessac L; Berdan LG; Bhatt DL; Bittner V; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Mahaffey KW; Moryusef A; Pordy R; Roe MT; Rorick T; Sasiela WJ; Shirodaria C; Szarek M; Tamby JF; Tricoci P; White H; Zeiher A; Steg PG
    Am Heart J; 2014 Nov; 168(5):682-9. PubMed ID: 25440796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reverse vessel remodeling but not coronary plaque regression could predict future cardiovascular events in ACS patients with intensive statin therapy--the extended JAPAN-ACS study.
    Miyauchi K; Daida H; Morimoto T; Hiro T; Kimura T; Nakagawa Y; Yamagishi M; Ozaki Y; Kadota K; Kimura K; Hirayama A; Kimura K; Hasegawa Y; Uchiyama S; Matsuzaki M;
    Circ J; 2012; 76(4):825-32. PubMed ID: 22451449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Event Rates and Risk Factors for Recurrent Cardiovascular Events and Mortality in a Contemporary Post Acute Coronary Syndrome Population Representing 239 234 Patients During 2005 to 2018 in the United States.
    Steen DL; Khan I; Andrade K; Koumas A; Giugliano RP
    J Am Heart Assoc; 2022 May; 11(9):e022198. PubMed ID: 35475346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
    Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
    Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study).
    Fox KA; Carruthers KF; Dunbar DR; Graham C; Manning JR; De Raedt H; Buysschaert I; Lambrechts D; Van de Werf F
    Eur Heart J; 2010 Nov; 31(22):2755-64. PubMed ID: 20805110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
    Lee HY; Cooke CE; Robertson TA
    J Manag Care Pharm; 2008 Apr; 14(3):271-80. PubMed ID: 18439049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial.
    Mani P; Puri R; Schwartz GG; Nissen SE; Shao M; Kastelein JJP; Menon V; Lincoff AM; Nicholls SJ
    JAMA Cardiol; 2019 Apr; 4(4):314-320. PubMed ID: 30840024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of ezetimibe coadministered with statins on cardiovascular events following acute coronary syndrome: a 3-year population-based retrospective cohort study in Taiwan.
    Lin CF; Gau CS; Wu FL; Hsiao FY; Bai CH; Shen LJ
    Clin Ther; 2011 Sep; 33(9):1120-31. PubMed ID: 21872930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-density lipoprotein cholesterol of less than 70 mg/dL is associated with fewer cardiovascular events in acute coronary syndrome patients: a real-life cohort in Thailand.
    Chinwong D; Patumanond J; Chinwong S; Siriwattana K; Gunaparn S; Hall JJ; Phrommintikul A
    Ther Clin Risk Manag; 2015; 11():659-67. PubMed ID: 25987839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry.
    Guedeney P; Baber U; Claessen B; Aquino M; Camaj A; Sorrentino S; Vogel B; Farhan S; Faggioni M; Chandrasekhar J; Kalkman DN; Kovacic JC; Sweeny J; Barman N; Moreno P; Vijay P; Shah S; Dangas G; Kini A; Sharma S; Mehran R
    Am Heart J; 2019 Jan; 207():10-18. PubMed ID: 30404046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.